Navigation Links
Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
Date:12/14/2009

ng localized and advanced prostate cancer. LHRH therapy slows the growth of prostate cancer by suppressing the production of testosterone in the testicles. Over time, this decreased level of testosterone can, however, cause bone loss. Men, on average, lose about 0.5 percent to 1 percent of their bone mineral density every year. That loss can increase to about 4 percent to 13 percent per year in men on long-term ADT.

Given the risk of bone loss with ADT therapy, NCCN recommends that men with prostate cancer discuss the risk with their oncologist and personal physician as well as undergo frequent monitoring for osteoporosis using the NOF's guidelines for the general population. The guidelines include recommendations for calcium supplements (1200 mg daily) and vitamin D (800-1,000 IU daily) for all men over age 50 years and additional treatment for men who have a greater than or equal to 3 percent likelihood of suffering a hip fracture or greater than or equal to 20 percent likelihood of suffering a major osteoporosis-related fracture within the next 10 years.

Along with getting the daily recommended amounts of calcium and vitamin D, the NOF also recommends older men protect their bone health by exercising regularly (weight-bearing and muscle-strengthening exercises), avoiding smoking and excessive alcohol, and talking to their doctor about a bone mineral density test. Prescription medication that helps protect against bone loss also might be an option for patients at high risk for fracture.

"Watson is committed to urologic health," said Fred Wilkinson, Executive Vice President, Global Brands at Watson. "Our new supplement program will help physicians encourage their prostate cancer patients who are on long-term androgen deprivation therapy to make a commitment to good bone health."

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading global specialty pharmaceutical compa
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Present at Credit Suisse Healthcare Conference
8. Watson Files FDA Application for Generic Rozerem(R)
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , Aug. 3, 2015 Par Pharmaceutical ... conference call on Friday, August 7, 2015 at 9:00 ... the second quarter ended June 30, 2015.  Par is ... to the public in its filings with the Securities ... available on its website by following the instructions at ...
(Date:8/3/2015)... , Aug. 3, 2015 OmniSeq, LLC ... Institute to the OmniSeq SM Genomic Network.  ... Cancer Institute (RPCI) and announced it was making ... a physician-driven, collaborative approach to genomic diagnostics that ... Cancer Institute is a rapidly expanding, multidisciplinary cancer ...
(Date:8/3/2015)...  Sage Analytics ( www.sageanalytics.com ), the developers of ... systems, announced its sponsorship of the California Cannabis Industry ... number of tickets are available for groups or individuals ... while enjoying an open bar, buffet dinner and hors ... Bay at sunset. With the legislative session ...
Breaking Medicine Technology:OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 2OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 3Sage Analytics Sponsors California Cannabis Industry Association Bay Area Cruise FUNdraiser 2
... YORK, April 9, 2008 Intra-Cellular Therapies, ... ongoing development,programs for ITI-007, the Company,s first-in-class ... and ITI-722,a low-dose formulation of ITI-007, which ... respectively. These new data demonstrate,ITI-007 has preclinical ...
... ... - Preliminary Phase I/II results to be presented in June at 2008 ... ... ), a clinical-stage biopharmaceutical company,focused on oncology, announced today that it has advanced CR011-vcMMAE, ...
Cached Medicine Technology:Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722 2Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722 3CuraGen Advances CR011-vcMMAE into Phase II 2CuraGen Advances CR011-vcMMAE into Phase II 3CuraGen Advances CR011-vcMMAE into Phase II 4
(Date:8/3/2015)... ... August 03, 2015 , ... The Workgroup for Electronic Data Interchange ... to create efficiencies in healthcare information exchange, announced the release of its findings from ... Human Services (HHS) Secretary, WEDI shared survey results and recommendations , ...
(Date:8/3/2015)... Angeles, California (PRWEB) , ... August 03, 2015 ... ... on the Atlanta Journal Constitution, the new Lifetime reality series, “Atlanta Plastic” ... who performs and who receives plastic surgery, with its predominantly African-American cast of ...
(Date:8/3/2015)... ... August 03, 2015 , ... According to an opinion piece published July 28 by ... to one pound of weight loss may not be accurate. While this system may work ... pound of fat varies – based both on the individual and at what point that ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... They know ... Providence St. Vincent Medical Center offers some of the best care in the ... neurosurgeon and neurointerventionalist, achieved the fastest average blood clot removal time in the country. ...
(Date:8/3/2015)... Pennsylvania (PRWEB) , ... August 03, 2015 , ... Bayer ... Yaz and Yasmin related claims in which a claimant alleged to have suffered an ... related to the birth control pills, Yaz, Yasmin and Ocella, has been ongoing for ...
Breaking Medicine News(10 mins):Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 2Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 3Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 4Health News:Article on Lifetime’s New “Atlanta Plastic” Reality Series Underlines the Diversity of Today’s Plastic Surgery Patients, Says Plastic Surgeon Dr. J 2Health News:Article on Lifetime’s New “Atlanta Plastic” Reality Series Underlines the Diversity of Today’s Plastic Surgery Patients, Says Plastic Surgeon Dr. J 3Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 2Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 3Health News:Bayer Agrees To Settle Yaz Aterial Blood Clot Lawsuits 2
... reflect results of new study , , FRIDAY, Jan. 18 (HealthDay ... American women carries a risk of serious blood clots that ... control pill, the U.S. Food and Drug Administration warned ... study that discovered the increased danger, the agency said it ...
... in Vegan Diet War, WASHINGTON, Jan. 18 ... the misleading Physicians Committee,for Responsible Medicine (PCRM) for ... which sued eight restaurant chains this week,over the ... been exposed,in Newsweek and The New York Times ...
... the United States Food and,Drug Administration (FDA) has ... cholesterol lowering medication also indicated for,improving glycemic control ... in,combination with metformin, sulfonylureas, or insulin, when these ... anti-diabetic agents., The ADA estimates that 20.8 ...
... Jan. 18 175 students from,the Academy of Columbus, ... the sixth annual Give Kids A Smile! Day state ... state kick-off will be held in the Atrium at ... from,The Ohio State University College of Dentistry, legislators and ...
... aggressive disease in 2 men taking the product , , ... product described as a dietary supplement appears to have ... two men, researchers report. , "There were things on ... components in the product that were not on the ...
... Part of Available Resources-, JACKSONVILLE, Fla., Jan. ... group of returning wounded veterans are the most ... has expanded,their ever-evolving battery of programs and services ... initiative., The Warriors to Work (WtoW) program ...
Cached Medicine News:Health News:FDA Warns Clot Risk Higher in Birth Control Patch Than Pill 2Health News:FDA Warns Clot Risk Higher in Birth Control Patch Than Pill 3Health News:Phony 'Physicians Committee' Suing Restaurants is Animal-Rights Trojan Horse, says CCF 2Health News:MultiVu Video Feed: WELCHOL (R) (COLESEVELAM HCL) RECEIVES FDA APPROVAL FOR GLUCOSE CONTROL IN ADULTS WITH TYPE 2 DIABETES MELITUS 2Health News:Statehouse Atrium to be Site for Children's Dental Access Event - Ohio Legislators to Mingle With Children and Dentists for This Free Care Event! 2Health News:Mislabled Supplement Spurred Prostate Cancer: Report 2Health News:Mislabled Supplement Spurred Prostate Cancer: Report 3Health News:Wounded Warrior Project (WWP) Expands Service Offerings for Injured Soldiers with the New 'Warriors to Work' Program 2
... HIV-1 Genotyping: The genome of ... in an infected patient, especially in response ... mutations have been shown to render the ... drugs, diminishing the effectiveness of the treatment.,The ...
EIA for Donor Screening. Synthetic peptide Enzyme Immunoassay (EIA) for the detection of antibodies to Human Immunodeficiency Virus Types 1 and/or 2,(HIV-1 and HIV-2) in human serum, plasma or ca...
... The Reveal Rapid HIV-1 Antibody Test (Reveal ... This test detects antibodies in human serum ... by the body in response to HIV ... MedMiras proprietary flow-through membrane technology, and is ...
... The OraQuick ADVANCE ... is a single-use, qualitative ... to Human Immunodeficiency Virus ... Type 2 (HIV-2) in ...
Medicine Products: